Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer

Partner | Cancer Centers | <b>Cedars-Sinai Cancer</b>

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Monica M. Mita, MD, co-director, Experimental Therapeutics, professor of medicine, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, discusses treatment selection for patients with estrogen receptor (ER)–positive, HER2-negative breast cancer.

Several therapeutic options have emerged in ER-positive, HER2-negative breast cancer that prolong survival and improve quality of life, Mita explains. Typically, for patients in this population who are not in visceral crisis, which would indicate an immediate need for chemotherapeutic intervention, treatment with CDK4/6 inhibitors is the standard frontline option, Mita says.

Selecting between available CDK4/6 inhibitors is largely based on physician preference, Mita explains. However, factors including patient age, comorbidities, performance status, prior toxicities, and prior treatments should be considered during treatment selection, concludes Mita.